An Adaptogen: Withaferin A Ameliorates in Vitro and in Vivo Pulmonary Fibrosis by Modulating the Interplay of Fibrotic, Matricelluar Proteins, and Cytokines

Pulmonary fibrosis (PF) is chronic lung disease with only two FDA approved clinically available drugs, with limited safety profile. Inadequate therapy motivated us to explore the effect of vimentin inhibitor Withaferin A, as an anti-fibrotic agent against TGF-β1-induced in vitro fibrotic events and...

Descripción completa

Detalles Bibliográficos
Autores principales: Bale, Swarna, Venkatesh, Pooladanda, Sunkoju, Manoj, Godugu, Chandraiah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874319/
https://www.ncbi.nlm.nih.gov/pubmed/29623041
http://dx.doi.org/10.3389/fphar.2018.00248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874319/
https://www.ncbi.nlm.nih.gov/pubmed/29623041
http://dx.doi.org/10.3389/fphar.2018.00248

Ejemplares similares